Arcutis Biotherapeutics ARQT
Arcutis Biotherapeutics, Inc. · Nasdaq · Pharmaceutical Preparations
$31.45-0.73%close on Oct. 28, 2026 · volume 1.7M · Yahoo Finance
Price, last 47 sessions
Our coverage
Nothing published yet.
Insider buying and selling
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Oct. 15, 2026 | Howard G. Welgus director | Sold 10b5-1 plan | 4,728 | $26.93 | $127,325 |
| Sept. 16, 2026 | Masaru Matsuda See Remarks | Sold 10b5-1 plan | 3,674 | $25.00 | $91,853 |
| Sept. 15, 2026 | Howard G. Welgus director | Sold 10b5-1 plan | 4,730 | $24.18 | $114,371 |
| Sept. 8, 2026 | Masaru Matsuda See Remarks | Sold 10b5-1 plan | 9,989 | $25.03 | $249,986 |
| Aug. 27, 2026 | Terrie Curran director | Sold | 38,200 | $25.03 | $956,123 |
| Aug. 20, 2026 | Terrie Curran director | Sold | 1,072 | $26.04 | $27,912 |
| Aug. 19, 2026 | Patrick Burnett See Remarks | Sold | 1,697 | $27.00 | $45,819 |
| Aug. 17, 2026 | Howard G. Welgus director | Sold 10b5-1 plan | 4,730 | $26.18 | $123,835 |
| Aug. 12, 2026 | Patrick Burnett See Remarks | Sold | 6,700 | $26.08 | $174,767 |
| Aug. 11, 2026 | Patrick Burnett See Remarks | Sold | 8,300 | $26.52 | $220,129 |
| Aug. 3, 2026 | Patrick Burnett See Remarks | Sold 10b5-1 plan | 955 | $26.12 | $24,942 |
| Aug. 3, 2026 | Masaru Matsuda See Remarks | Sold 10b5-1 plan | 1,230 | $26.12 | $32,124 |
Latest 12 of 13. Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Recent SEC filings
All 19 →Departure/appointment of directors or officers · Regulation FD disclosure · Financial statements and exhibits
AI summary, unreviewedArcutis Biotherapeutics Appoints Dr. Robert Scott, Former AbbVie CMO, to Board of Directors